GSK Collaborates with Vir to Develop Treatment for COVID-19

GSK Collaborates with Vir to Develop Treatment for COVID-19

Shots:

  • GSK to invest in Vir with $250M at $37.73, a 10% premium to the closing share price on Friday, March 27, 2020 and enters into an agreement to develop a potential Ab treatment against COVID-19
  • The alliance will leverage Vir’s mAb platform to identify Ab that can be used as preventive option addressing COVID-1 and utilize GSK’s expertise in functional genomics and combine their capabilities in CRISPR screening and AI to identify anti-coronavirus compounds targeting the cellular host genes
  • Initially, the companies will accelerate Vir’s Ab, VIR-7831 and VIR-7832 that demonstrates high affinity in neutralizing SARS-CoV-2 and is expected to be accelerated into P-II studies within the next 3-5mos.

Click here ­to­ read full press release/ article | Ref: GSK | Image: GSK